Azaindazole compounds as CCR1 receptor antagonists

US8063065B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Brian Nicholas Cook · Danbury, US
• Darren Di Salvo · New Milford, US
• Christian Harcken · New Milford, US
• Daniel Kuzmich · Clovis, US
• Thomas Wai-Ho Lee · Danbury, US
• Pingrong Liu · Southbury, US
• John Lord · New York, US
• Can Mao · Philadelphia, US
• Jochen NEU · Mittelbiberach, DE
• Brian Christopher Raudenbush · Charlton, US
• Hossein Razavi · Danbury, US
• Alan David Swinamer · Bethel, US

Key dates

• Filing date: Dec 16, 2010
• Grant date: Nov 22, 2011
• Expiry date: Dec 16, 2030

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P37/08
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.Also disclosed are methods of making and methods of using same.